Aerosolized @entity2841 ( XXXX ) therapy in @entity5 .

@entity1 @entity137 @entity242 @entity5 @entity1358 @entity358 @entity2841 @entity320
A recent phase I study of aerosolized @entity2841 ( @entity2841 ) in @entity1 with malignant metastases to the lungs demonstrated excellent tolerance and possible efficacy. This therapy was offered to other @entity1 who refused "standard" treatment or when no effective therapy was available. Forty-five @entity1 were treated; 40 had pulmonary metastases. Aerosolized @entity2841 (250 microg/dose) was administered twice a day using a 1 week on, 1 week off schedule. The mean interval between diagnosis and therapy was 32 months. Twenty-four @entity1 had disease stabilization or partial regression. The mean duration of benefit was 10 months. This benefit was noted in 8 of 13 with a @entity242 , 6 of 14 with @entity320 , and 5 of 12 with @entity1358 . Eighteen @entity1 reported mostly self-limiting @entity137 . The frequency of certain @entity320 -specific T lymphocytes in 1 @entity1 with stable disease was found to have increased 10-fold after therapy. Aerosolized @entity2841 appears to have limited but promising efficacy in treatment of @entity358 . In one @entity1 , we have evidence of upregulation of @entity320 -specific cytotoxic T-cells. Further study is warranted to understand the impact of this therapy on the natural history of @entity5 .
